San Diego-based Oncternal Therapeutics is closing shop. To oversee the wind-down process, the company will retain only one employee: Craig Jalbert, a principal of the accounting firm Verdolino & Lowey, P.C. He will act as Oncternal’s president, CEO, treasurer, secretary and sole member of its board of directors. All remaining executives, directors and employees of Oncternal have resigned, though it’s not immediately clear how many people will be directly affected by the company’s closure. In September 2024, the biotech downsized by 37%, corresponding to about 10 employees, including its Chief Medical Officer Salim Yazji.
All entries for: Company Closure
July 2, 2025
Oncternal Therapeutics
Company Closure
San Diego, CA
1-50 employees
Disease Area: Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule
May 8, 2025
Third Harmonic Bio
Company Closure
San Francisco, CA
1-50 employees
Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing to sell the asset while liquidating the business.
Disease Area: Gastrointestinal, Immune Diseases, Multiple, Respiratory Diseases
Drug Type: Small Molecule
April 10, 2025
Vincerx Pharma
Company Closure
Palo Alto, CA
1-50 employees
After terminating a non binding letter of intent for a potential merger with QumulusAI, Vincerx Pharma will wind down, the company announced April 8. The San Mateo, California–based biotech, whose pipeline focused on addressing unmet medical needs for cancer patients, is also exploring monetization of assets and outlicensing opportunities.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule